Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI3506 Phase 1 in Healthy and COPD Subjects
NCT03096795Phase 1Completed
- Sponsor
- MedImmune
- Start
- May 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (14 arms), sponsored by MedImmune. Primary endpoints: Treatment-emergent Adverse Events at Day 169, Grade 2 or More Toxicity Grades in Laboratory Parameters at Day 169 and 5 more. Started May 2017; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03096795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096795.